Amarin Corporation plc · NASDAQ:AMRN
Amarin — Q4 2024 Earnings Presentation
18 slides from Amarin's earnings presentation, Mar 12, 2025
Slide 1: Fourth Quarter Financial Results/2024 Business Update & Conference Call
Fourth Quarter Financial Results/2024 Business Update & Conference Call March 12, 2025
Slide 2: Forward-Looking Statements & Disclaimer
Forward-Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, res
Slide 3: Today's Agenda
Today’s Agenda 01 STATE OF THE BUSINESS: AN UPDATE Aaron Berg, President & CEO 02 FOURTH QUARTER 2024 FINANCIAL RESULTS Peter Fishman, SVP, Chief Financial Officer 03 VASCEPA/VAZKEPA RESEARCH UPDATE Steve Ketchum, EVP, Chief Scientific Officer 04 CLOSING REMARKS Aaron Berg, President & CEO 05 Q&A
Slide 4: State of the Business: An Update
01 STATE OF THE BUSINESS: AN UPDATE Aaron Berg President & CEO
Slide 5: VASCEPA: A Complementary Therapy With Growing Momentum & Opportunity
BUSINESS UPDATE VASCEPA: A COMPLEMENTARY THERAPY WITH GROWING MOMENTUM & OPPORTUNITY TO DELIVER CONTINUED GLOBAL IMPACT VASCEPA/VAZKEPA – FOUNDATION SCIENCE REGULATORY PROGRESS COMMERCIAL FOOTPRINT REVENUE GENERATION REDUCE-IT Outcomes Approvals in 49+ Global Launched in 20+ Markets Efficient Revenu
Slide 6: Full Year 2024 & Early 2025: Accomplishments
BUSINESS UPDATE FULL YEAR 2024 & EARLY 2025: ACCOMPLISHMENTS STRATEGIC HIGHLIGHTS OPERATIONAL HIGHLIGHTS FINANCIAL HIGHLIGHTS New European IP granted, Europe: Spain, UK & CEE continue to lead early $228.6 million in total revenues achieved extending VAZKEPA exclusivity European VAZKEPA growth;
Slide 7: Fourth Quarter 2024 Financial Results
02 FOURTH QUARTER 2024 FINANCIAL RESULTS Peter Fishman Senior Vice President, Chief Financial Officer
Slide 8: Q4 2024: P&L Highlights
FINANCIAL RESULTS Q4 2024: P&L HIGHLIGHTS Q4 ’24 TOTAL REVENUE OF $62.3M Q4 ‘24 OPERATING EXPENSES • US: $44.2 million; ~32% reduction vs. • ROW: $11.9M1; ~184% increase vs Q4 2023 • ~$7M reduction in Total Operating Expenses Q4 ‘24 vs. Q4 ‘23 Q4 2023 due to lower NSP and volume driven by Chinese la
Slide 9: Year-End 2024: Cash Balance Remains Substantial
FINANCIAL RESULTS YEAR-END 2024: CASH BALANCE REMAINS SUBSTANTIAL; 2-YEAR TRACK RECORD OF PRUDENT CASH DEPLOYMENT CASH ($M) $321 $321 $311 $313 $305 $308 $307 $306 YEAR END 2024 $294 • Cash Balance of $294M • No debt • Inventory draw down continues alongside progress renegotiating supply purchase ag
Slide 10: Committed to Maintaining Nasdaq Listing
FINANCIAL RESULTS COMMITTED TO MAINTAINING NASDAQ LISTING ANNOUNCED 1-FOR-20 RATIO CHANGE ACTION INTENDED RESULT Intent to implement a ratio change on Ratio Change will increase per share our American Depositary Shares market price of Amarin’s ADSs in order (“ADS”) from 1 ADS representing 1 to m
Slide 11: VASCEPA/VAZKEPA Research Update
03 VASCEPA/VAZKEPA RESEARCH UPDATE Steve Ketchum Executive Vice President, Chief Scientific Officer
Slide 12: VASCEPA: Strong Science, Medical Advocacy & Regulatory Foundation
PUBLISHED DATA VASCEPA: STRONG SCIENCE, MEDICAL ADVOCACY & REGULATORY FOUNDATION TO DRIVE PATIENT-CARE IMPACT SCIENCE, MEDICAL ADVOCACY & REGULATORY FOUNDATION MEDICAL SCIENCE REGULATORY ADVOCACY Since 2011, supported 500+ Secured more than 50 Approvals in 49 markets publications on science clini
Slide 13: Published in JAHA: REDUCE-IT Analysis Shows Clear Outcomes Benefit
PUBLISHED DATA PUBLISHED IN JAHA: REDUCE-IT ANALYSIS SHOWS CLEAR VASCEPA OUTCOMES BENEFIT IN PATIENTS WITH WELL-CONTROLLED LDL-C (<55mg/dL) Icosapent Ethyl (IPE) reduced REDUCE-IT data has composite cardiovascular consistently shown robust endpoint events regardless relative and absolute risk of bas
Slide 14: ACC.25: Features Supported Abstracts on EPA Mechanisms
IN VITRO MECHANISTIC DATA ACC.25: FEATURES SUPPORTED ABSTRACTS ON EPA MECHANISMS, POTENTIAL COMPLEMENTARITY WITH OTHER AGENTS MORE RAPID OXIDATION OF LIPOPROTEIN(A) [LP(A)]- ADDITION OF EICOSAPENTAENOIC ACID (EPA) ENRICHED PLASMA COMPARED TO SMALL DENSE- AND TO A GLP-1 AGONIST ENHANCED EXPRESSION OF
Slide 15: Closing Remarks
04 CLOSING REMARKS Aaron Berg President & CEO
Slide 16: 2025: Amarin Priorities & Opportunities
CLOSING REMARKS 2025: AMARIN PRIORITIES & OPPORTUNITIES • Complete 1-for-20 ADS Ratio Change process to increase per share market price of ADSs in order to maintain Nasdaq listing. CVD REMAINS #1 KILLER • Drive access and revenue growth in Europe and Rest of the World. WORLDWIDE1, • Drive efficient
Slide 17: Q&A
05 Q&A
Slide 18: Thank You
Vascepa Vazkepa (icosapent ethyl) (icosapent ethyl) THANK YOU